1
|
Arraras J, Illarramendi J, Manterola-Burgaleta A, de la Cruz S, Zarandona U, Ibañez B, Salgado E, Visus I, Barrado M, Teijeira L, Martinez E, Vera R. Quality of Life of breast cancer patients with COVID-19 disease. Eur J Cancer 2022. [PMCID: PMC9671787 DOI: 10.1016/s0959-8049(22)01515-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- J.I. Arraras
- Servicio Navarro de Salud/Complejo Hospitalario de Navarra, Oncology Departments, Pamplona, Spain
| | - J.J. Illarramendi
- Hospital Universitario de Navarra, Medical Oncology, Pamplona, Spain
| | | | - S. de la Cruz
- Hospital Universitario de Navarra, Medical Oncology, Pamplona, Spain
| | - U. Zarandona
- Hospital Universitario de Navarra, Oncology Departments, Pamplona, Spain
| | - B. Ibañez
- Navarrabiomed- Departamento de Salud-UPNA, Methodology, Pamplona, Spain
| | - E. Salgado
- Hospital Universitario de Navarra, Medical Oncology, Pamplona, Spain
| | - I. Visus
- Hospital Universitario de Navarra, Radiotherapeutic Oncology, Pamplona, Spain
| | - M. Barrado
- Hospital Universitario de Navarra, Radiotherapeutic Oncology, Pamplona, Spain
| | - L. Teijeira
- Hospital Universitario de Navarra, Medical Oncology, Pamplona, Spain
| | - E. Martinez
- Hospital Universitario de Navarra, Radiotherapeutic Oncology, Pamplona, Spain
| | - R. Vera
- Hospital Universitario de Navarra, Medical Oncology, Pamplona, Spain
| |
Collapse
|
8
|
Campian J, Gladstone D, Ambady P, Ye X, King K, Borrello I, Petrik S, Golightly M, Holdhoff M, Grossman S, Bhardwaj R, Chakravadhanula M, Ozols V, Georges J, Carlson E, Hampton C, Decker W, Chiba Y, Hashimoto N, Kagawa N, Hirayama R, Tsuboi A, Oji Y, Oka Y, Sugiyama H, Yoshimine T, Choi B, Gedeon P, Herndon J, Sanchez-Perez L, Mitchell D, Bigner D, Sampson J, Choi YA, Pandya H, Gibo DM, Debinski W, Cloughesy TF, Liau LM, Chiocca EA, Jolly DJ, Robbins JM, Ostertag D, Ibanez CE, Gruber HE, Kasahara N, Vogelbaum MA, Kesari S, Mikkelsen T, Kalkanis S, Landolfi J, Bloomfield S, Foltz G, Pertschuk D, Everson R, Jin R, Safaee M, Lisiero D, Odesa S, Liau L, Prins R, Gholamin S, Mitra SS, Richard CE, Achrol A, Kahn SA, Volkmer AK, Volkmer JP, Willingham S, Kong D, Shin JJ, Monje-Deisseroth M, Cho YJ, Weissman I, Cheshier SH, Kanemura Y, Sumida M, Yoshioka E, Yamamoto A, Kanematsu D, Takada A, Nonaka M, Nakajima S, Goto S, Kamigaki T, Takahara M, Maekawa R, Shofuda T, Moriuchi S, Yamasaki M, Kebudi R, Cakir FB, Gorgun O, Agaoglu FY, Darendeliler E, Lin Y, Wang Y, Qiu X, Jiang T, Lin Y, Wang Y, Jiang T, Zhang G, Wang J, Okada H, Butterfield L, Hamilton R, Drappatz J, Engh J, Amankulor N, Lively M, Chan M, Salazar A, Potter D, Shaw E, Lieberman F, Pandya H, Choi Y, Park J, Phuphanich S, Wheeler C, Rudnick J, Hu J, Mazer M, Wang H, Nuno M, Guevarra A, Sanchez C, Fan X, Ji J, Chu R, Bender J, Hawkins E, Black K, Yu J, Reap E, Archer G, Sanchez-Perez L, Norberg P, Schmittling R, Nair S, Cui X, Snyder D, Chandramohan V, Choi B, Kuan CT, Mitchell D, Bigner D, Yan H, Sampson J, Reardon D, Li G, Recht L, Fink K, Nabors L, Tran D, Desjardins A, Chandramouli N, Duic JP, Groves M, Clarke A, Hawthorne T, Green J, Yellin M, Sampson J, Rigakos G, Spyri O, Nomikos P, Stavridi F, Grossi I, Theodorakopoulou I, Assi A, Kouvatseas G, Papadopoulou E, Nasioulas G, Labropoulos S, Razis E, Rudnick J, Ravi A, Sanchez C, Tang DN, Hu J, Yu J, Sharma P, Black K, Sengupta S, Sampath P, Soto H, Erickson K, Malone C, Hickey M, Ha E, Young E, Ellingson B, Prins R, Liau L, Kruse C, Sul J, Hilf N, Kutscher S, Schoor O, Lindner J, Reinhardt C, Kreisl T, Iwamoto F, Fine H, Singh-Jasuja H, Teijeira L, Gil-Arnaiz I, Hernandez-Marin B, Martinez-Aguillo M, Sanchez SDLC, Viudez A, Hernandez-Garcia I, Lecumberri MJ, Grandez R, de Lascoiti AF, Garcia RV, Thomas A, Fisher J, Baron U, Olek S, Rhodes H, Gui J, Hampton T, Tafe L, Tsongalis G, Lefferts J, Wishart H, Kleen J, Miller M, Ernstoff M, Fadul C, Vlahovic G, Desjardins A, Peters K, Ranjan T, Herndon J, Friedman A, Friedman H, Bigner D, Archer G, Lally-Goss D, Sampson J, Wainwright D, Dey M, Chang A, Cheng Y, Han Y, Lesniak M, Weller M, Kaulich K, Hentschel B, Felsberg J, Gramatzki D, Pietsch T, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger G, Yu J, Rudnick J, Hu J, Phuphanich S, Mazer M, Wang H, Xu M, Nuno M, Patil C, Chu R, Black K, Wheeler C. IMMUNOTHERAPY/BIOLOGICAL THERAPIES. Neuro Oncol 2013; 15:iii68-iii74. [PMCID: PMC3823893 DOI: 10.1093/neuonc/not178] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/09/2023] Open
|
12
|
Arrazubi V, Suarez J, Guerrero D, Cambra K, Gomez Dorronsoro ML, Arias F, Balen E, Teijeira L, Vera R. Polymorphisms of thymidylate synthase as prognostic factor in rectal cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
433 Background: Neoadjuvant fluoropyrimidine-based chemotherapy (ChT) plus radiotherapy (Rt) is a standard approach for locally advanced rectal cancer. Polymorphisms of thymidylate synthase (TS), the target for fluoropyrimidines, are recognized prognostic factors in colon cancer. The aim of this study was to evaluate the prognostic value of the polymorphisms of TS in rectal cancer after neoadjuvant ChT plus Rt. Methods: We studied one-hundred consecutive patients with stage II/III rectal cancer between November 2001 and March 2009. Patients underwent surgery 6-8 weeks after neoadjuvant Rt (5,040 cGy) plus fluoropyrimidine-based ChT. DNA was extracted from paraffin embedded biopsies. TS1494del6 and 5′-28bp repeat +G/C SNP polymorphisms were determined. Results: Sixty-seven percent were men and median age was 67 years. ypT stage was: T0 9%, T1 2%, T2 27%, T3 60% and T4 2%; 32% had locoregional adenopathies. The median follow-up was 45 months and relapse occurred in 20% of patients. Polimorphisms could be determined in 98% of pt: -6bp/-6bp 10%, - 6bp/+6bp 39%, +6bp/+6bp 51% and 2R/2R 72%, 2R/3R 21%, 3R/3R 6%. The grade of pathological tumour regression was not associated with polymorphisms. Relapses occurred in 40% of patients -6bp/-6bp, 22% of patients -6bp/+6bp and 21% of patients +6bp/+6bp. The difference in disease- free survival (DFS) between the first and the third groups was stadistically significative (p=0.049). No relation between 5′-28bp repeat +G/C SNP polymorphism and DFS was found. Conclusions: Our data suggest that the TS1494del6 polimorphism may be an important prognosis factor in rectal cancer receiving neoadjuvant chemoradiotherapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- V. Arrazubi
- Service of Medical Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain; Complejo Hospitalario de Navarra, Pamplona, Spain
| | - J. Suarez
- Service of Medical Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain; Complejo Hospitalario de Navarra, Pamplona, Spain
| | - D. Guerrero
- Service of Medical Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain; Complejo Hospitalario de Navarra, Pamplona, Spain
| | - K. Cambra
- Service of Medical Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain; Complejo Hospitalario de Navarra, Pamplona, Spain
| | - M. L. Gomez Dorronsoro
- Service of Medical Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain; Complejo Hospitalario de Navarra, Pamplona, Spain
| | - F. Arias
- Service of Medical Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain; Complejo Hospitalario de Navarra, Pamplona, Spain
| | - E. Balen
- Service of Medical Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain; Complejo Hospitalario de Navarra, Pamplona, Spain
| | - L. Teijeira
- Service of Medical Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain; Complejo Hospitalario de Navarra, Pamplona, Spain
| | - R. Vera
- Service of Medical Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain; Complejo Hospitalario de Navarra, Pamplona, Spain
| |
Collapse
|